Platelet glycoprotein VI in the regulation of thrombus growth

Citation for published version (APA):

Document status and date:
Published: 01/01/2022

DOI:
10.26481/dis.20221004gp

Document Version:
Publisher's PDF, also known as Version of record

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

Link to publication

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above, please follow below link for the End User Agreement:
www.umlib.nl/taverne-license

Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.

Download date: 23 Aug. 2022
Summary
Glycoprotein VI (GPVI) is the major signalling receptor for collagen. Mouse studies have shown that GPVI is critical for arterial thrombus formation but has a limited contribution to haemostasis. Individuals with an inherited deficiency in GPVI also have only a mild bleeding diathesis. Together, these observations suggest that targeting GPVI may suppress arterial thrombosis while preserving haemostasis. The recent discovery that GPVI is also a receptor for fibrinogen and fibrin suggests that its role extends beyond the onset of thrombin formation. In addition, it raised question about the functional significance of these new interactions. Chapter 1 provides a general introduction to the work performed with emphasis on the roles of platelets in thrombosis and haemostasis, relevant platelet receptors and ligands, and the architecture of arterial thrombi. As an overarching hypothesis, I proposed that GPVI acts as a relevant signalling receptor for fibrin and fibrinogen in thrombus propagation and stability. Therefore, I investigated the relative contribution of collagen, fibrinogen and fibrin to thrombus growth and stability using inhibitors of GPVI and downstream tyrosine kinases. In Chapter 2, I examined the reasons for conflicting results in the literature on whether fibrin and fibrinogen bind to monomeric or dimeric GPVI. I analysed the differences between the various (dimeric and monomeric) GPVI constructs used by the groups involved in the contradictory results, the binding assays employed, and the methods used for fibrin generation. This analysis highlighted the importance of knowing the precise molecular structure of the various GPVI constructs and the role of charge interactions in the ligand binding. As some of the GPVI domains are highly charged, it was concluded that the intramolecular charges gave rise to diverse orientations of the various GPVI constructs, thereby accounting for the discrepant results. Hence, the different forms of GPVI constructs, along with a different use of reagents and techniques could explain the discrepant results.

In Chapter 3, I explored the role of platelet GPVI in flow-dependent thrombus formation on collagen and non-collagen surfaces in the
presence or absence of coagulation. For the studies, I used blood from four homozygous and three heterozygous individuals, from three unrelated families, with an inherited mutation in the GP6 gene, which prevents GPVI expression on platelets. The results show that GPVI is critical for flow-dependent platelet aggregation and phosphatidylserine exposure on both collagen and non-collagen surfaces, whereas it is not required for platelet adhesion. In addition, I confirmed that GPVI can be activated through charge interactions as spreading of platelets on collagen, VWF and negatively charged glass was reduced or abolished with platelets lacking expression of GPVI. Given the unique presentation of GPVI-deficient individuals in the Chilean population, we sequenced the GP6 exon 6 in 1212 DNA samples, representative of the Chilean population, and calculated that about 4079 individuals carrying the GP6 mutation may be living in Chile without genetic diagnosis or recognised bleeding phenotype.

In Chapter 4, I studied the role of GPVI in supporting platelet adhesion, activation, and aggregation under flow conditions on a range of fibrin and fibrinogen surfaces, in comparison to a collagen surface. In the study platelet responses elicited by GPVI were compared to those relying on integrin αIIbβ3 and GPIb-V-IX. Using Fab 9O12 (blocking GPVI), PRT-060318 (inhibiting Syk tyrosine kinase) and blood from Glanzmann patients lacking integrin αIIbβ3, I concluded that αIIbβ3 is key for platelet adhesion to fibrin and fibrinogen and that it synergises with GPVI in provoking adhesion-dependent platelet activation. Furthermore, I showed that thrombi formed on fibrin and fibrinogen are relatively small when compared to collagen, with platelets showing P-selectin expression, transient cytosolic Ca\(^{2+}\) rises and a low phosphatidylserine exposure. In Chapter 5 I investigated the effect of two small molecules, losartan and honokiol, reported as GPVI antagonists, on platelet responses. Both compounds indeed decreased thrombus formation on collagen, but they were not specific for GPVI, as they also impaired platelet activation induced by CLEC-2 agonists.
Chapter 6 observes whether the tyrosine kinase cascade downstream GPVI and integrin αIIbβ3 is involved in the process of thrombus stabilization, and whether this can be targeted to cause disaggregation of platelets. To do that, flow studies were performed on immobilised collagen and human plaque material under non-coagulating conditions, thus preventing the formation of fibrin. Aggregate stability was challenged by post-perfusion of Syk, Src or Btk inhibitors. In addition, the effects of these inhibitors were compared to antagonism of the secondary mediators of platelet activation, ADP and thromboxane A₂ (TxA₂). We found that inhibition of Syk and Src increased platelet disaggregation of preformed thrombi, both on collagen and plaque material, to a similar extent as blockage of ADP and TxA₂. No additive effect was seen when tyrosine kinase inhibitors were combined with ADP and TxA₂ blockers, suggesting that the pathways act in synergy to maintain thrombus stability. In contrast, selective inhibition of Btk did not significantly impair the stability of the preformed aggregates. We concluded that targeting Syk might be promising to disrupt the thrombus shell, a region of the thrombus which is devoid of fibrin and consists of loosely aggregated platelets.

The review of Chapter 7 provides an inventory of the literature evidence supporting a role of platelet GPVI in venous thromboembolism, based on findings with humans and mice. This concerned studies that related GPVI to experimental thrombosis, pulmonary thromboembolism and thrombo-inflammation. In humans, a common variant rs1613662 in the GP6 gene is linked to venous thromboembolism. Overall, the literature shows emerging evidence for platelet GPVI acting in the venous part of the circulation, including leukocyte-dependent thrombo-inflammation, venous thromboembolism, pulmonary thromboembolism and cancer metastasis. We critically evaluated whether fibrin might be the responsible GPVI agonist under venous thrombosis conditions. A general conclusion was that platelet GPVI may be a suitable co-target in the prevention of venous thrombosis due to its role in thrombus
consolidation and platelet-leukocyte complex formation. **Chapter 8**
discusses the findings of this thesis, noting the importance of having an
antagonist specific for GPVI interaction with fibrin and fibrinogen given
the prospective of targeting GPVI and its signalling in thrombotic
complications.